Dandan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dandan Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Xingang Li
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University
6 shared publications - Heng Guo
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China
3 shared publications - Yingming Zheng
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China
3 shared publications - Aiping Wen
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China
2 shared publications - Xiaozhen Wang
Central Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publications Yingming Zheng
Beijing Key Laboratory of Clinical-Based Innovative Drug R&D of Traditional Chinese Medicine, Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China
2 shared publications
Latest Publications
- 8 April 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (9) , 14055-14065
Real-world prescription patterns of guideline-recommended therapies in heart failure across China
Comprehensive real-world studies on guideline-recommended therapies for heart failure (HF) in China are lacking. This study aimed to describe the prescription patterns of guideline-recommended therapies and identify factors influencing sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) use in a nationwide patient cohort. We analyzed prescriptions from HF patients across 134 hospitals in nine Chinese cities (January 2018 to June 2023). Prescription trends for core guideline-recommended HF medication classes were assessed, and multivariable logistic regression identified factors associated with SGLT2 inhibitors use. Among 1,852,053 HF patients (median age 71; 58.35% male), β-blockers and MRAs use remained stable over time. ARNI utilization increased, correspondingly reducing ACEI/ARB use. SGLT2 inhibitors use rose significantly from 2020. Factors positively associated with SGLT2 inhibitors use included male sex (OR 1.34, 95% CI 1.31-1.36), age 18-59 years, treatment in tertiary hospitals, and diagnoses of atrial fibrillation (OR 1.34, 95% CI 1.31-1.38), dyslipidemia (OR 1.57, 95% CI 1.52-1.61), or diabetes (OR 6.28, 95% CI 6.15-6.41). This first large-scale, multicenter retrospective analysis delineates real-world HF medication usage patterns in China. The findings reveal a progressive uptake of newer therapies such as SGLT2 inhibitors, with prescription rates increasing substantially following guideline updates. SGLT2 inhibitors use, while consistent with recent evidence, is influenced by demographic, clinical, and systemic factors, indicating significant potential for optimization to maximize clinical benefits.
- 8 April 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (9) , 14055-14065
Real-world prescription patterns of guideline-recommended therapies in heart failure across China
Comprehensive real-world studies on guideline-recommended therapies for heart failure (HF) in China are lacking. This study aimed to describe the prescription patterns of guideline-recommended therapies and identify factors influencing sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) use in a nationwide patient cohort. We analyzed prescriptions from HF patients across 134 hospitals in nine Chinese cities (January 2018 to June 2023). Prescription trends for core guideline-recommended HF medication classes were assessed, and multivariable logistic regression identified factors associated with SGLT2 inhibitors use. Among 1,852,053 HF patients (median age 71; 58.35% male), β-blockers and MRAs use remained stable over time. ARNI utilization increased, correspondingly reducing ACEI/ARB use. SGLT2 inhibitors use rose significantly from 2020. Factors positively associated with SGLT2 inhibitors use included male sex (OR 1.34, 95% CI 1.31-1.36), age 18-59 years, treatment in tertiary hospitals, and diagnoses of atrial fibrillation (OR 1.34, 95% CI 1.31-1.38), dyslipidemia (OR 1.57, 95% CI 1.52-1.61), or diabetes (OR 6.28, 95% CI 6.15-6.41). This first large-scale, multicenter retrospective analysis delineates real-world HF medication usage patterns in China. The findings reveal a progressive uptake of newer therapies such as SGLT2 inhibitors, with prescription rates increasing substantially following guideline updates. SGLT2 inhibitors use, while consistent with recent evidence, is influenced by demographic, clinical, and systemic factors, indicating significant potential for optimization to maximize clinical benefits.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 4539-4548
Real-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China
Purpose: To determine the real-world patterns and extent of potential drug-drug interactions (DDIs) related to nirmatrelvir/ritonavir (NMVr) in China. Patients and Methods: Data on NMVr-treated patients from over 160 hospitals across 9 Chinese cities from January 2022 to December 2023 were extracted from the Hospital Prescription Analysis (HPA) database, which was established in Beijing in 1997 to promote rational medication use in China. Grade C, D and X DDIs from the Lexicomp database were defined as clinically significant and analyzed in this study. Statistical analyses included descriptive statistics (continuous variables as mean ± SD; categorical variables as counts and percentages) and multivariate binary logistic regression, which was used to identify factors associated with potential DDIs, with adjustment for confounding variables (sex, age, cities, number of co-administered drugs, comorbidities). Analyses were performed using R software (v4.2.2) with P < 0.05 as statistically significant, and figures were generated via GraphPad Prism (v10.3.1). Results: Of 15,567 patients receiving NMVr, the mean age was 62.4 ± 18.2 years, and 53.1% were male. 8542 patients received at least one co-administration, and 5391 patients exhibited at least one potential DDI. A total of 10,694 potential DDIs were identified, with a breakdown of 8310 grade C, 2093 grade D and 291 grade X. Systemic corticosteroids (n=3608) and drugs for obstructive airway diseases (n=2220) had the highest frequencies in grade C DDIs, and the lipid modifying agents (n=601) in grade D DDIs, and cardiac therapy drugs (n=130) in grade X DDIs. Co-administration of drugs significantly increased odds of potential DDIs with the risk escalating markedly as the number of drugs increased, and the comorbidities of hypertension (odds ratio [OR]=1.50), asthma (OR=4.28) and mental disorders (OR=7.02) significantly increased it as well. Conclusion: In this large-scale cross-sectional study in China, approximately one-third of the patients treated with NMVr were at risk of clinically significant potential DDIs, highlighting the importance of making efforts to diminish these risks, such as close monitoring and dose adjustment.
- 1 August 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 4539-4548
Open AccessReal-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China
Purpose: To determine the real-world patterns and extent of potential drug-drug interactions (DDIs) related to nirmatrelvir/ritonavir (NMVr) in China. Patients and Methods: Data on NMVr-treated patients from over 160 hospitals across 9 Chinese cities from January 2022 to December 2023 were extracted from the Hospital Prescription Analysis (HPA) database, which was established in Beijing in 1997 to promote rational medication use in China. Grade C, D and X DDIs from the Lexicomp database were defined as clinically significant and analyzed in this study. Statistical analyses included descriptive statistics (continuous variables as mean ± SD; categorical variables as counts and percentages) and multivariate binary logistic regression, which was used to identify factors associated with potential DDIs, with adjustment for confounding variables (sex, age, cities, number of co-administered drugs, comorbidities). Analyses were performed using R software (v4.2.2) with P < 0.05 as statistically significant, and figures were generated via GraphPad Prism (v10.3.1). Results: Of 15,567 patients receiving NMVr, the mean age was 62.4 ± 18.2 years, and 53.1% were male. 8542 patients received at least one co-administration, and 5391 patients exhibited at least one potential DDI. A total of 10,694 potential DDIs were identified, with a breakdown of 8310 grade C, 2093 grade D and 291 grade X. Systemic corticosteroids (n=3608) and drugs for obstructive airway diseases (n=2220) had the highest frequencies in grade C DDIs, and the lipid modifying agents (n=601) in grade D DDIs, and cardiac therapy drugs (n=130) in grade X DDIs. Co-administration of drugs significantly increased odds of potential DDIs with the risk escalating markedly as the number of drugs increased, and the comorbidities of hypertension (odds ratio [OR]=1.50), asthma (OR=4.28) and mental disorders (OR=7.02) significantly increased it as well. Conclusion: In this large-scale cross-sectional study in China, approximately one-third of the patients treated with NMVr were at risk of clinically significant potential DDIs, highlighting the importance of making efforts to diminish these risks, such as close monitoring and dose adjustment.
- Open Access
- 4 October 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e51635
Engine of Innovation in Hospital Pharmacy: Applications and Reflections of ChatGPT
Hospital pharmacy plays an important role in ensuring medical care quality and safety, especially in the area of drug information retrieval, therapy guidance, and drug-drug interaction management. ChatGPT is a powerful artificial intelligence language model that can generate natural-language texts. Here, we explored the applications and reflections of ChatGPT in hospital pharmacy, where it may enhance the quality and efficiency of pharmaceutical care. We also explored ChatGPT’s prospects in hospital pharmacy and discussed its working principle, diverse applications, and practical cases in daily operations and scientific research. Meanwhile, the challenges and limitations of ChatGPT, such as data privacy, ethical issues, bias and discrimination, and human oversight, are discussed. ChatGPT is a promising tool for hospital pharmacy, but it requires careful evaluation and validation before it can be integrated into clinical practice. Some suggestions for future research and development of ChatGPT in hospital pharmacy are provided.
- 4 October 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e51635
Open AccessEngine of Innovation in Hospital Pharmacy: Applications and Reflections of ChatGPT
Hospital pharmacy plays an important role in ensuring medical care quality and safety, especially in the area of drug information retrieval, therapy guidance, and drug-drug interaction management. ChatGPT is a powerful artificial intelligence language model that can generate natural-language texts. Here, we explored the applications and reflections of ChatGPT in hospital pharmacy, where it may enhance the quality and efficiency of pharmaceutical care. We also explored ChatGPT’s prospects in hospital pharmacy and discussed its working principle, diverse applications, and practical cases in daily operations and scientific research. Meanwhile, the challenges and limitations of ChatGPT, such as data privacy, ethical issues, bias and discrimination, and human oversight, are discussed. ChatGPT is a promising tool for hospital pharmacy, but it requires careful evaluation and validation before it can be integrated into clinical practice. Some suggestions for future research and development of ChatGPT in hospital pharmacy are provided.
- 8 June 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (11) , 8853-8862
Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants
The dosing of fluconazole for young infants remains empirical because of the limited pharmacokinetic (PK) data. We aimed to establish a population PK model and assess the systematic exposure-response of commonly used regimens of fluconazole in Chinese infants. We included infants with a postnatal age of less than 120 days and received intravenous fluconazole. Both scheduled and scavenged plasma samples were collected, and fluconzaole concentration was determined by a validated ultra-performance liquid chromatography-tandem mass spectrometry assay. Population PK analysis was conducted using Phoenix NLME, and then Monte Carlo simulation was conducted to predict the probability of target attainment (PTA) of empirically used regimens of both prophylactic and therapeutic purposes. Based on 304 plasma samples from 183 young infants, fluconazole concentration data was best described by a one-compartment model with first-order elimination. Gestational Age (GA), postnatal age (PNA), and body weight (BW) were included in the final model as CL = 0.02*(GA/214)2.77*(PNA/13)0.24*exp(nCL); V = 1.56*(BW/1435)0.90*exp(nV). Model validation revealed the final model had qualified stability and acceptable predictive properties. Monte Carlo simulation indicated that under the same minimum inhibitory concentration (MIC) value and administration regimen, PTA decreased with GA and PNA. The commonly used prophylactic regimens can meet the clinical need, while higher doses might be needed for treatment of invasive candidiasis. This population PK model of fluconazole discriminated the impact of GA and PNA on CL and BW on V. Dosing adjustment was needed according to the GA and PNA of infants to achieve targeted exposures.
- 8 June 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (11) , 8853-8862
Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants
The dosing of fluconazole for young infants remains empirical because of the limited pharmacokinetic (PK) data. We aimed to establish a population PK model and assess the systematic exposure-response of commonly used regimens of fluconazole in Chinese infants. We included infants with a postnatal age of less than 120 days and received intravenous fluconazole. Both scheduled and scavenged plasma samples were collected, and fluconzaole concentration was determined by a validated ultra-performance liquid chromatography-tandem mass spectrometry assay. Population PK analysis was conducted using Phoenix NLME, and then Monte Carlo simulation was conducted to predict the probability of target attainment (PTA) of empirically used regimens of both prophylactic and therapeutic purposes. Based on 304 plasma samples from 183 young infants, fluconazole concentration data was best described by a one-compartment model with first-order elimination. Gestational Age (GA), postnatal age (PNA), and body weight (BW) were included in the final model as CL = 0.02*(GA/214)2.77*(PNA/13)0.24*exp(nCL); V = 1.56*(BW/1435)0.90*exp(nV). Model validation revealed the final model had qualified stability and acceptable predictive properties. Monte Carlo simulation indicated that under the same minimum inhibitory concentration (MIC) value and administration regimen, PTA decreased with GA and PNA. The commonly used prophylactic regimens can meet the clinical need, while higher doses might be needed for treatment of invasive candidiasis. This population PK model of fluconazole discriminated the impact of GA and PNA on CL and BW on V. Dosing adjustment was needed according to the GA and PNA of infants to achieve targeted exposures.
- 1 April 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (15) , 1167-1177
Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis
Background: Metabolism of oral anticoagulants (OAC) is affected by P-glycoprotein (P-gp)/ CYP3A4 enzyme. However, the P-gp/CYP3A4 inhibitors are unavoidably used with OACs. Methods: Medline, Cochrane, and Embase were systematically searched for randomized controlled trials and cohort studies from inception till 23rd November, 2022 to assess the safety and effectiveness of OACs when concomitantly used with P-gp/CYP3A4 inhibitors. The primary outcomes were major bleeding and gastrointestinal (GI) bleeding. Secondary outcomes were stroke/systemic embolism (SE), all-cause mortality, any bleeding as well as intracranial hemorrhage (ICH). We estimated summary odds ratios (OR) with 95% credible intervals (CI) using pairwise and network meta-analysis with random effects Results: A total of 11 studies involving 37,973 patients were included. When concomitantly used with P-pg/ CYP3A4 inhibitors, network meta-analysis indicated that dabigatran, apixaban, and edoxaban were associated with significantly lower risk of major bleeding compared to rivaroxaban, with ORs of 0.56, 0.51 and 0.48, respectively. Rivaroxaban and dabigatran were associated with a significantly increased risk of GI bleeding than warfarin, apixaban and edoxaban. Dabigatran and apixaban were linked with significantly lower risk of any bleeding compared with warfarin (ORs were 0.75 and 0.68, respectively) or rivaroxaban (ORs were 0.67 and 0.60, respectively). Apixaban (OR 0.32) and edoxaban (OR 0.35) were associated with a lower risk of ICH compared with warfarin. There was no difference between any OACs in terms of stroke/SE or all-cause mortality. Conclusion: When concomitantly used with P-gp/CYP3A4 inhibitors, apixaban and edoxaban were associated with a lower risk of bleeding, though no significant difference in effectiveness was observed among all OACs.
- 1 April 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (15) , 1167-1177
Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis
Background: Metabolism of oral anticoagulants (OAC) is affected by P-glycoprotein (P-gp)/ CYP3A4 enzyme. However, the P-gp/CYP3A4 inhibitors are unavoidably used with OACs. Methods: Medline, Cochrane, and Embase were systematically searched for randomized controlled trials and cohort studies from inception till 23rd November, 2022 to assess the safety and effectiveness of OACs when concomitantly used with P-gp/CYP3A4 inhibitors. The primary outcomes were major bleeding and gastrointestinal (GI) bleeding. Secondary outcomes were stroke/systemic embolism (SE), all-cause mortality, any bleeding as well as intracranial hemorrhage (ICH). We estimated summary odds ratios (OR) with 95% credible intervals (CI) using pairwise and network meta-analysis with random effects Results: A total of 11 studies involving 37,973 patients were included. When concomitantly used with P-pg/ CYP3A4 inhibitors, network meta-analysis indicated that dabigatran, apixaban, and edoxaban were associated with significantly lower risk of major bleeding compared to rivaroxaban, with ORs of 0.56, 0.51 and 0.48, respectively. Rivaroxaban and dabigatran were associated with a significantly increased risk of GI bleeding than warfarin, apixaban and edoxaban. Dabigatran and apixaban were linked with significantly lower risk of any bleeding compared with warfarin (ORs were 0.75 and 0.68, respectively) or rivaroxaban (ORs were 0.67 and 0.60, respectively). Apixaban (OR 0.32) and edoxaban (OR 0.35) were associated with a lower risk of ICH compared with warfarin. There was no difference between any OACs in terms of stroke/SE or all-cause mortality. Conclusion: When concomitantly used with P-gp/CYP3A4 inhibitors, apixaban and edoxaban were associated with a lower risk of bleeding, though no significant difference in effectiveness was observed among all OACs.
- Open Access
- 6 August 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Engine of Innovation in Hospital Pharmacy: Applications and Reflections of ChatGPT (Preprint)
UNSTRUCTURED Hospital pharmacy plays an important role in ensuring medical care quality and safety, especially in the area of drug information retrieval, therapy guidance, and drug-drug interaction management. ChatGPT is a powerful artificial intelligence language model that can generate natural-language texts. Here, we explored the applications and reflections of ChatGPT in hospital pharmacy, where it may enhance the quality and efficiency of pharmaceutical care. We also explored ChatGPT’s prospects in hospital pharmacy and discussed its working principle, diverse applications, and practical cases in daily operations and scientific research. Meanwhile, the challenges and limitations of ChatGPT, such as data privacy, ethical issues, bias and discrimination, and human oversight, are discussed. ChatGPT is a promising tool for hospital pharmacy, but it requires careful evaluation and validation before it can be integrated into clinical practice. Some suggestions for future research and development of ChatGPT in hospital pharmacy are provided.
- 6 August 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEngine of Innovation in Hospital Pharmacy: Applications and Reflections of ChatGPT (Preprint)
UNSTRUCTURED Hospital pharmacy plays an important role in ensuring medical care quality and safety, especially in the area of drug information retrieval, therapy guidance, and drug-drug interaction management. ChatGPT is a powerful artificial intelligence language model that can generate natural-language texts. Here, we explored the applications and reflections of ChatGPT in hospital pharmacy, where it may enhance the quality and efficiency of pharmaceutical care. We also explored ChatGPT’s prospects in hospital pharmacy and discussed its working principle, diverse applications, and practical cases in daily operations and scientific research. Meanwhile, the challenges and limitations of ChatGPT, such as data privacy, ethical issues, bias and discrimination, and human oversight, are discussed. ChatGPT is a promising tool for hospital pharmacy, but it requires careful evaluation and validation before it can be integrated into clinical practice. Some suggestions for future research and development of ChatGPT in hospital pharmacy are provided.
- Open Access
- 31 May 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (6) , 424-433
Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
Atrial fibrillation,NOACs,warfarin,meta-analysis
- 31 May 2022
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (6) , 424-433
Open AccessLow-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
Atrial fibrillation,NOACs,warfarin,meta-analysis
- Open Access
- 7 March 2022
- Published by Wiley in Cardiology Research and Practice
- Vol. 2022, 1-10
Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
Objective. We aimed to further investigate the efficacy and safety of low-dose NOACs by performing a meta-analysis of cohort studies. Background. Meta-analyses of randomized controlled trials (RCTs) have demonstrated that low-dose non-vitamin K antagonist oral anticoagulants (NOACs) showed inferior efficacy compared with standard-dose NOACs, although they are still frequently prescribed for patients with atrial fibrillation (AF) in the clinical practice. Methods. Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE were systematically searched from the inception to September 9, 2021, for cohort studies that compared the efficacy and/or safety of low-dose NOACs in patients with AF. The primary outcomes were ischemic stroke and major bleeding, and the secondary outcomes were mortality, intracranial hemorrhage (ICH), and gastrointestinal hemorrhage (GH). Hazard ratios (HRs) and 95 confidence intervals (CIs) were estimated with the random-effect model. Results. Twenty-five publications involving 487856 patients with AF were included. Compared with standard-dose NOACs, low-dose NOACs had comparable risks of ischemic stroke (HR=1.03, 95 CI 0.96 to 1.11), major bleeding (HR=1.12, 95 CI 0.97 to 1.28), ICH (HR=1.09, 95 CI 0.88 to 1.36), and GH (HR=1.11, 95 CI 0.92 to 1.33), except for a higher risk of mortality (HR=1.41, 95 CI 1.21 to 1.65). Compared with warfarin, low-dose NOACs were associated with lower risks of ischemic stroke (HR=0.72, 95 CI .67 to 0.78), mortality (HR=0.67, 95 CI 0.59 to 0.77), major bleeding (HR=0.64, 95 CI 0.53 to 0.79), ICH (HR=0.57, 95 CI 0.42 to 0.77), and GH (HR=0.78, 95 CI 0.64 to 0.95). Conclusions. Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.
- 7 March 2022
- Published by Wiley in Cardiology Research and Practice
- Vol. 2022, 1-10
Open AccessReal-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
Objective. We aimed to further investigate the efficacy and safety of low-dose NOACs by performing a meta-analysis of cohort studies. Background. Meta-analyses of randomized controlled trials (RCTs) have demonstrated that low-dose non-vitamin K antagonist oral anticoagulants (NOACs) showed inferior efficacy compared with standard-dose NOACs, although they are still frequently prescribed for patients with atrial fibrillation (AF) in the clinical practice. Methods. Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and MEDLINE were systematically searched from the inception to September 9, 2021, for cohort studies that compared the efficacy and/or safety of low-dose NOACs in patients with AF. The primary outcomes were ischemic stroke and major bleeding, and the secondary outcomes were mortality, intracranial hemorrhage (ICH), and gastrointestinal hemorrhage (GH). Hazard ratios (HRs) and 95 confidence intervals (CIs) were estimated with the random-effect model. Results. Twenty-five publications involving 487856 patients with AF were included. Compared with standard-dose NOACs, low-dose NOACs had comparable risks of ischemic stroke (HR=1.03, 95 CI 0.96 to 1.11), major bleeding (HR=1.12, 95 CI 0.97 to 1.28), ICH (HR=1.09, 95 CI 0.88 to 1.36), and GH (HR=1.11, 95 CI 0.92 to 1.33), except for a higher risk of mortality (HR=1.41, 95 CI 1.21 to 1.65). Compared with warfarin, low-dose NOACs were associated with lower risks of ischemic stroke (HR=0.72, 95 CI .67 to 0.78), mortality (HR=0.67, 95 CI 0.59 to 0.77), major bleeding (HR=0.64, 95 CI 0.53 to 0.79), ICH (HR=0.57, 95 CI 0.42 to 0.77), and GH (HR=0.78, 95 CI 0.64 to 0.95). Conclusions. Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.